By

Thomas Armstrong
I read an online article today from Benzinga, a financial media company that empowers its readers with daily actionable market analysis and commentary.  It reported on a new ADHD drug that the FDA had just approved, called Cotempla XR-OTD, a methylphenidate extended release orally-disintegrating tablet for treating ADHD in kids aged 6-17.  According to BMO...
Read More
A new study of Scottish children published in the JAMA Pediatrics this week, suggests that the 1.0% of subjects (N= 7413) that were being medicated for attention deficit hyperactivity disorder had poorer outcomes on a wide range of measures compared with others in the study (N=766,244). The outcomes included: poor academic attainment, unauthorized absence from...
Read More
I have a new article on the site MiddleWeb, which focuses on the importance of understanding recent brain research and how it can inform the creation of ”brain friendly” practices for young adolescents.  I was a junior high school teacher, a professor of courses in childhood and adolescent development, and a consultant to middle schools,...
Read More
This is a blog post that appeared on ASCD’s InService blog, April 19, 2017.  It talks about an article I wrote for the April, 2017 issue of Educational Leadership entitled Neurodiversity:  The Future of Special Education? ”I was a special education teacher for several years back in the 1970s and 1980s.  Although I’d been trained at...
Read More
I’ve been concerned about the lack of input that children and adolescents diagnosed with ADHD have relating to their diagnosis and treatment.  Now a new study in the May 2017 issue of the Community Mental Health Journal reports that children with a diagnosis of ADHD want to talk with their doctors about their diagnosis and the...
Read More
1 2 3 62

Article Archives